What the GHK-Cu research peptide did in skin
Getting an ingredient into skin is one hurdle. Showing that it helps people is the next one.
Getting in is only the first question
What do delivery measurements tell us about a visible benefit?
Copper got through skin pieces
GHK is a peptide made from three amino acids, the building blocks of proteins. GHK-Cu is that peptide holding copper. In skincare, you may see the name copper tripeptide-1.
In a 2011 study on pieces of human skin, copper from a GHK-Cu preparation passed into and through skin layers. Some stayed in the tissue. Researchers were testing delivery outside the body.
Here's the detail we don't want to lose: they measured copper. That doesn't establish that the whole peptide reached a target. It also doesn't tell us whether a person's wrinkles or skin comfort changed.
The human test gave a mixed answer
An earlier 2006 trial after laser skin resurfacing compared skincare with and without GHK-Cu. Only 13 people completed it. It wasn't a follow-up to the 2011 delivery paper. We're comparing the questions they asked, and the small size matters when weighing this result.
Computer analysis and assessors who didn't know which treatment people received found no clear improvement in redness, wrinkles or overall skin quality. People using the GHK-Cu products did report higher satisfaction. Both findings belong in the story.
Being happier with a skincare routine counts as a different answer from a measured improvement in wrinkles. We don't have to dismiss satisfaction. We do have to say what it means.
These people were recovering from laser treatment. The result can't settle the question for every cream or every skin concern. It does show why a finding about copper getting through skin isn't enough on its own.
The claim has to stop where the test stops
We'd like a stronger human answer before making broad claims about skin improvement. An injection needs its own evidence, too. Changing how a substance enters the body changes the question.
A skincare name is no assurance about an injection
GHK-Cu has no FDA-approved drug product. Small topical studies can't rule out uncommon reactions. Human injection safety remains unestablished.
FDA raises concerns about injectable GHK-Cu, including immune reactions related to clumping and impurities. Its page current as of April 22, 2026 lists the injectable nomination as withdrawn. That isn't approval or permission to compound.
For non-injectable GHK-Cu, FDA's list updated May 14, 2026 places it in Category 1, meaning under evaluation. Under the interim policy, FDA does not intend to act against compounders using Category 1 ingredients if the policy's conditions are met. That is not approval or a guarantee that compounding is lawful. It doesn't apply to injections. A licensed clinician can assess a skin concern and discuss suitable options.